NCT04258826View on ClinicalTrials.gov

A Study to Evaluate LY3154207 on the Brain of Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

January 15, 2021

Primary Completion Date

January 28, 2022

Study Completion Date

January 28, 2022

Conditions
Healthy
Interventions
DRUG

LY3154207

LY3154207 administered orally.

DRUG

Placebo

Placebo administered orally.

Trial Locations (1)

60659

Northwestern University, Chicago

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT04258826 - A Study to Evaluate LY3154207 on the Brain of Healthy Participants | Biotech Hunter | Biotech Hunter